Genetic polymorphism of CYP2D6 influences susceptibility to papillary thyroid cancer

Clinical Endocrinology

Volumn 67, Issue 2, 2007, Pages 180-183

  Lemos, Manuel C ^a,b,c   Carrilho, Francisco ^b   Rodrigues, Fernando ^b,d   Coutinho, Eduarda ^c   Gomes, Leonor ^b   Carvalheiro, Manuela ^b   Regateiro, Fernando J ^c  

^a UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^b CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d Instituto Portugues de Oncologia Francisco Gentil Centro Regional de Oncologia de Coimbra SA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6;

ADULT; ALLELE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CONTROLLED STUDY; ENZYME METABOLISM; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION MAPPING; RETROSPECTIVE STUDY; THYROID CANCER;

ADENOCARCINOMA, PAPILLARY; ADULT; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CYTOCHROME P-450 CYP2D6; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; THYROID NEOPLASMS;

EID: 34447512808     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.02858.x     Document Type: Article

References (23)

1. Al-Brahim, N. Asa, S.L. (2006) Papillary thyroid carcinoma: an overview. Archives of Pathology and Laboratory Medicine, 130, 1057 1062.
2. Kondo, T., Ezzat, S. Asa, S.L. (2006) Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nature Reviews Cancer, 6, 292 306.
3. Hard, G.C. (1998) Recent developments in the investigation of thyroid regulation and thyroid carcinogenesis. Environmental Health Perspectives, 106, 427 436.
4. Autrup, H. (2000) Genetic polymorphisms in human xenobiotica metabolizing enzymes as susceptibility factors in toxic response. Mutation Research, 464, 65 76.
5. Ingelman-Sundberg, M. (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics Journal, 5, 6 13.
6. Wilkinson, G.R. (2005) Drug metabolism and variability among patients in drug response. New England Journal of Medicine, 352, 2211 2221.
7. Gough, A.C., Miles, J.S., Spurr, N.K., Moss, J.E., Gaedigk, A., Eichelbaum, M. Wolf, C.R. (1990) Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature, 347, 773 776.
8. Agundez, J.A. (2004) Cytochrome P450 gene polymorphism and cancer. Current Drug Metabolism, 5, 211 224.
9. Agundez, J.A., Rodriguez, I., Olivera, M., Ladero, J.M., Garcia, M.A., Ribera, J.M. Benitez, J. (1997) CYP2D6, NAT2 and CYP2E1 genetic polymorphisms in nonagenarians. Age and Ageing, 26, 147 151.
10. Muiras, M.L., Verasdonck, P., Cottet, F. Schächter, F. (1998) Lack of association between human longevity and genetic polymorphisms in drug-metabolizing enzymes at the NAT2, GSTM1 and CYP2D6 loci. Human Genetics, 102, 526 532.
11. Garte, S., Gaspari, L., Alexandrie, A.K., Ambrosone, C., Autrup, H., Autrup, J.L., Baranova, H., Bathum, L., Benhamou, S., Boffetta, P., Bouchardy, C., Breskvar, K., Brockmoller, J., Cascorbi, I., Clapper, M.L., Coutelle, C., Daly, A., Dell'Omo, M., Dolzan, V., Dresler, C.M., Fryer, A., Haugen, A., Hein, D.W., Hildesheim, A., Hirvonen, A., Hsieh, L.L., Ingelman-Sundberg, M., Kalina, I., Kang, D., Kihara, M., Kiyohara, C., Kremers, P., Lazarus, P., Le Marchand, L., Lechner, M.C., van Lieshout, E.M., London, S., Manni, J.J., Maugard, C.M., Morita, S., Nazar-Stewart, V., Noda, K., Oda, Y., Parl, F.F., Pastorelli, R., Persson, I., Peters, W.H., Rannug, A., Rebbeck, T., Risch, A., Roelandt, L., Romkes, M., Ryberg, D., Salagovic, J., Schoket, B., Seidegard, J., Shields, P.G., Sim, E., Sinnet, D., Strange, R.C., Stucker, I., Sugimura, H., To-Figueras, J. Vineis, P., Yu, M.C. Taioli, E. (2001) Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiology, Biomarkers & Prevention, 10, 1239 1248.
12. Sobin, L.H. Wittekind, Ch, eds 1997) UICC: TNM Classification of Malignant Tumours, 5th edn. John Wiley, New York.
13. Fleming, I.D., Cooper, J.S., Hensen, D.E., Hutter, R.V.P., Kennedy, B.J., Murphy, G.P., O'Sullivan, B., Sobin, L.H. Yarbro, J.W., eds 1997) AJCC: Cancer Staging Manual, 5th edn. Lippincott-Raven, Philadelphia.
14. Lemos, M.C. Regateiro, F.J. (1998) N-acetyltransferase genotypes in the Portuguese population. Pharmacogenetics, 8, 561 564.
15. Lemos, M.C., Cabrita, F.J., Silva, H.A., Vivan, M., Plácido, F. Regateiro, F.J. (1999) Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias. Carcinogenesis, 20, 1225 1229.
16. Rostami-Hodjegan, A., Lennard, M.S., Woods, H.F. Tucker, G.T. (1998) Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease. Pharmacogenetics, 8, 227 238.
17. Guengerich, F.P. (2000) Metabolism of chemical carcinogens. Carcinogenesis, 21, 345 351.
18. Kim, D. Guengerich, F.P. (2005) Cytochrome P450 activation of arylamines and heterocyclic amines. Annual Review of Pharmacology and Toxicology, 45, 27 49.
19. Morari, E.C., Leite, J.L., Granja, F., da Assumpcao, L.V. Ward, L.S. (2002) The null genotype of glutathione s-transferase M1 and T1 locus increases the risk for thyroid cancer. Cancer Epidemiology, Biomarkers & Prevention, 11, 1485 1488.
20. Gaspar, J., Rodrigues, S., Gil, O.M., Manita, I., Ferreira, T.C., Limbert, E., Goncalves, L., Pina, J.E. Rueff, J. (2004) Combined effects of glutathione S-transferase polymorphisms and thyroid cancer risk. Cancer Genetics and Cytogenetics, 151, 60 67.
21. Ho, T., Zhao, C., Zheng, R., Liu, Z., Wei, Q. Sturgis, E.M. (2006) Glutathione S-transferase polymorphisms and risk of differentiated thyroid carcinomas: a case-control analysis. Archives of Otolaryngology - Head and Neck Surgery, 132, 756 761.
22. Kirsch-Volders, M., Mateuca, R.A., Roelants, M., Tremp, A., Zeiger, E., Bonassi, S., Holland, N., Chang, W.P., Aka, P.V., Deboeck, M., Godderis, L., Haufroid, V., Ishikawa, H., Laffon, B., Marcos, R., Migliore, L., Norppa, H., Teixeira, J.P., Zijno, A. Fenech, M. (2006) The effects of GSTM1 and GSTT1 polymorphisms on micronucleus frequencies in human lymphocytes in vivo. Cancer Epidemiology, Biomarkers & Prevention, 15, 1038 1042.
23. Sobrinho-Simoes, M., Preto, A., Rocha, A.S., Castro, P., Maximo, V., Fonseca, E. Soares, P. (2005) Molecular pathology of well-differentiated thyroid carcinomas. Virchows Archiv, 447, 787 793.